Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?

Abstract excerpt

Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Angina Pectoris
• Share to Arrhythmias, Cardiac
• Share to Long QT Syndrome